Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Menu Back to Regulatory-Strategy-and-EU-Pharmaceutical-Policy

Regulatory Strategy & EU Pharmaceutical Policy

The Regulatory Strategy & EU Pharmaceutical Policy track is composed of sessions addressing regulations and policies governing biopharmaceutical product development, approval, and maintenance. Themes will revolve around evolution of the European regulatory ecosystem and impacts for global development strategies. In the context of revision of the EU General Pharmaceutical Legislation as well as the Orphan Drug and Paediatric Regulations, sessions will focus on how the framework can be optimised to support regulatory science and the sustainability of innovation. Representatives from the European Commission, EMA, National European Health Authorities and other regulatory stakeholders will provide updates, insights, and discussion on current issues through interactive forums.

Who is This Track Designed For?

Regulatory strategy and policy professionals interested in exploring both the strategic implications of the evolving regulatory ecosystem as well as focused sessions on key aspects of regulation impacting the development of medicines.

25101-175w

The online program is now available. Explore the rich content we offer across 10 thought leadership tracks. 

View Searchable Programme

Topic Leader

Rebecca Lumsden

Rebecca Lumsden

Head of Regulatory Science & Policy EU/AMEE

Sanofi, United Kingdom

Tamara Di Carlantonio

Tamara Di Carlantonio

Regulatory Policy Lead

Roche, Basel

View Regulatory Strategy & EU Pharmaceutical Policy Sessions

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.